Hemab Therapeutics Holdings Inc. (COAG)
COAG trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$29.80
-1.94% on the day
Market cap
$1.4B
Small cap
Revenue
New registrant: no annual report filed under this company yet
Net income
New registrant: no annual report filed under this company yet
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | COAG on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2026 |
| SEC CIK | 0002114044 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials
New registrant: no annual report filed under this company yet.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B4 | 2026-05-01 |
| Latest quarterly / interim | 10-Q | 2026-08-11 |
| Latest current report | 8-K | 2026-09-24 |
Source: SEC EDGAR submissions feed, 50 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +4.5% |
| 1 month | -25.2% |
| 3 months | -32.7% |
| Year to date | Not enough price history |
| 1 year | Not enough price history |
| From 52-week high | -45.4% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| IMCR | Immunocore Holdings plc | $27.82 | -4.20% | $1.4B |
| MAZE | Maze Therapeutics Inc. | $26.66 | -3.75% | $1.5B |
| INBX | Inhibrx Biosciences Inc. | $87.08 | -3.81% | $1.3B |
| TSHA | Taysha Gene Therapies Inc. | $3.58 | -13.53% | $1.2B |
| REPL | Replimune Group Inc. | $12.11 | -7.34% | $1.1B |
| VOR | Vor Biopharma Inc. | $19.06 | -3.74% | $1.1B |
| VIR | Vir Biotechnology Inc. | $10.61 | -6.11% | $1.8B |
| MESO | Mesoblast Limited | $13.89 | -2.63% | $1.8B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier